Format

Send to

Choose Destination
Lung Cancer. 2019 Jan;127:138-145. doi: 10.1016/j.lungcan.2018.11.034. Epub 2018 Nov 29.

Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).

Author information

1
Latner Thoracic Surgery Laboratories, Division of Thoracic Surgery and Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada.
2
Department of Biology, University of Pisa, Via Derna 1, Pisa, Italy.
3
Division of Thoracic Surgery, Lung Center and International Mesothelioma Program, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
4
Division of Cancer Biology, Aichi Cancer Center Research Institute, Kanokoden 1-1, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
5
Department of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, 1211 Geneva 4, Switzerland.
6
Laboratory of Molecular Oncology, University Hospital Zurich, University of Zurich, 8044, Zürich, Switzerland.
7
Latner Thoracic Surgery Laboratories, Division of Thoracic Surgery and Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada. Electronic address: Marc.DePerrot@uhn.ca.

Abstract

Here we summarize the most recent update of mesothelioma research in basic science presented at the 14th iMig2018 international conference. The symposium of basic science track mainly focused on the drivers of mesothelioma initiation and progression, molecular pathogenesis, and perspectives on potential therapeutic approaches. This review covers several promising fields including strategies efficiently inhibiting YAP/TAZ functions or their critical downstream targets, heparanase inhibitors, RAN depletion, and MIF/CD74 inhibitors that may be developed as novel therapeutic approaches. In addition, targeting mesothelioma stem cells by depleting M2-polarized macrophages in tumor microenvironment or blocking Tnfsf18 (GITRL)-GITR signalling might be translated into therapeutic modalities in mesothelioma treatment.

KEYWORDS:

Asbestos exposure; International mesothelioma interest group (iMig); Malignant pleural mesothelioma (MPM); Molecular pathogenesis; Therapeutic approach

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center